Page last updated: 2024-08-18

pyrroles and Minimal Disease, Residual

pyrroles has been researched along with Minimal Disease, Residual in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Advani, AS; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, A; Kovacsovics, TJ; Lancet, JE; Levy, MY; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Voellinger, J; Walter, RB	1
Antonescu, CR; Dupont, J; Linkov, I; Maki, RG; Seandel, M; Shia, J	1
Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A	1

Trials

1 trial(s) available for pyrroles and Minimal Disease, Residual

Article	Year
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018, 09-13, Volume: 132, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzodiazepines; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Pyrroles; Sialic Acid Binding Ig-like Lectin 3; Survival Rate	2018

Article

Year

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Blood, 2018, 09-13, Volume: 132, Issue:11

Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzodiazepines; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Pyrroles; Sialic Acid Binding Ig-like Lectin 3; Survival Rate

2018

Other Studies

2 other study(ies) available for pyrroles and Minimal Disease, Residual

Article	Year
The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-15, Volume: 12, Issue:20 Pt 1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Neoplasm, Residual; Phosphotransferases; Pyrroles; Sunitinib; Treatment Outcome	2006
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome	2009

Article

Year

The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-15, Volume: 12, Issue:20 Pt 1

Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Neoplasm, Residual; Phosphotransferases; Pyrroles; Sunitinib; Treatment Outcome

2006

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:1

Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome

2009